32 min listen
Selected FXR Agonist PBC Studies: Conference Coverage of AASLD
Selected FXR Agonist PBC Studies: Conference Coverage of AASLD
ratings:
Length:
18 minutes
Released:
Dec 13, 2023
Format:
Podcast episode
Description
During the 2023 American Association for the Study of Liver Diseases conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-δ agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses topline results from several of these studies and more, including: A combination of 3 studies—HEROES, COBALT, and COBALT EC—that evaluated the real-world effectiveness and safety of second-line therapy in PBC where OCA was added to the treatment regimen of people with PBC with an incomplete response to ursodeoxycholic acid Lessons learned from a long-term outcomes study of people with PBCResults from 2 phase II studies of obeticholic acid plus bezafibrate in people with PBC who did not respond to or were intolerant of ursodeoxycholic acidPresenter:Kris V. Kowdley MD, FAASLD, FACP, FACGProfessor, Elson S. Floyd College of MedicineWashington State UniversityDirector, Liver Institute NorthwestSeattle, Washington Link to reviews of other PBC studies from AASLD 2023: https://bit.ly/3RvXXEI
Released:
Dec 13, 2023
Format:
Podcast episode
Titles in the series (100)
COVID-19: Answering the Questions, Part 11: In Part 11 of this ongoing COVID-19 series, listen to a brief update on the role of interferons in COVID-19 by Sharon R. Lewin AO, FRACP, PhD, FAHMS. by CCO Infectious Disease Podcast